AtriCure (NASDAQ:ATRC) Hits New 1-Year High – Time to Buy?

AtriCure, Inc. (NASDAQ:ATRC)’s share price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $55.94 and last traded at $55.5010, with a volume of 34758 shares traded. The stock had previously closed at $54.54.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ATRC. BTIG Research boosted their price objective on shares of AtriCure from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Monday, August 24th. Citigroup restated a “market outperform” rating on shares of AtriCure in a research report on Tuesday, July 21st. UBS Group decreased their price objective on AtriCure from $55.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday, July 28th. Raymond James Financial set a $52.00 price objective on AtriCure in a research report on Tuesday, July 21st. Finally, Weiss Ratings raised AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 19th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $52.00.

AtriCure Price Performance

The company has a quick ratio of 3.19, a current ratio of 4.22 and a debt-to-equity ratio of 0.14. The stock has a market capitalization of $2.80 billion, a PE ratio of 261.75 and a beta of 1.26. The firm’s fifty day moving average price is $42.41 and its two-hundred day moving average price is $33.56.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. The company had revenue of $153.60 million during the quarter, compared to analyst estimates of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same quarter in the previous year, the company posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, equities analysts predict that AtriCure, Inc. will post 0.29 earnings per share for the current year.

Insider Transactions at AtriCure

In related news, insider Salvatore Privitera sold 7,763 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $52.50, for a total value of $407,557.50. Following the transaction, the insider owned 150,921 shares of the company’s stock, valued at approximately $7,923,352.50. This trade represents a 4.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Sven Wehrwein sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $37.84, for a total transaction of $946,000.00. Following the sale, the director owned 40,518 shares of the company’s stock, valued at $1,533,201.12. This trade represents a 38.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 65,036 shares of company stock worth $2,758,687. 4.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On AtriCure

A number of institutional investors have recently bought and sold shares of ATRC. AQR Capital Management LLC lifted its position in AtriCure by 1.0% during the first quarter. AQR Capital Management LLC now owns 83,685 shares of the medical device company’s stock valued at $2,700,000 after purchasing an additional 837 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of AtriCure by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,146 shares of the medical device company’s stock worth $908,000 after buying an additional 1,230 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of AtriCure by 1.0% in the first quarter. Goldman Sachs Group Inc. now owns 862,668 shares of the medical device company’s stock worth $27,830,000 after buying an additional 8,956 shares during the period. Jane Street Group LLC lifted its position in shares of AtriCure by 658.3% during the 1st quarter. Jane Street Group LLC now owns 100,853 shares of the medical device company’s stock valued at $3,254,000 after buying an additional 87,553 shares in the last quarter. Finally, Strs Ohio purchased a new position in shares of AtriCure during the 1st quarter valued at about $158,000. 99.11% of the stock is owned by institutional investors.

About AtriCure

AtriCure, Inc (NASDAQ: ATRC) is a medical device company focused on the treatment of atrial fibrillation (AF) and related conditions. The company develops, manufactures and sells surgical and minimally invasive technologies designed to restore normal heart rhythm and reduce the risk of stroke associated with AF.

Its product portfolio includes the AtriClip system for excluding the left atrial appendage, the Isolator and Synergy systems for surgical ablation, and the cryoICE system, which uses cryothermal energy in cardiac procedures.